Peptinov is a Paris-based biotech start-up founded by Prof. Jean-François Zagury to develop innovative vaccines against non-infectious diseases (auto-immmune diseases, cancer, chronic pain).
Jean-Pierre Salles, Pharm.D., joined Peptinov as R&D Director. Jean-Pierre Salles is an expert in peptide synthesis and vaccine development.
Peptinov signs a collaboration agreement with a leading Animal Health corporation.
Peptinov starts the development of several anti-cancer vaccines.
Hervé de Kergrohen, MD, MBA, joined Peptinov as CEO. Hervé de Kergrohen has 25 years of experience in the management and financing of innovative life science companies.
Peptinov released an article on the safety, immunogenicity and efficacy of its anti-IL-6 active immunotherapy candidate in non-human primates in Scientific Reports (Nature Publishing Group). Article available on Scientific Reports’ website.
Selection by Direction Générale de l’Armement (DGA) for a RAPID grant to develop Peptinov’s anti-TNF small molecule inhibitors, in collaboration with industrial partners, over the following 3 years.
Laureate, FUI national grant program for the development of Peptinov’s anti-IL-1 vaccine, ensuring financing for this R&D program (performed in collaboration with industrial and academic partners) over the following 4 years.
Relocation of Peptinov’s laboratories to the Cochin Biotech Business Accelerator on the campus of Cochin Hospital.
The Cochin Biotech Business Accelerator hosting Peptinov’s labs.
Move of Peptinov’s laboratories to Paris Biotech incubator at Cochin Hospital, Paris.
Creation of Peptinov.